These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9430224)

  • 1. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
    Blake N; Lee S; Redchenko I; Thomas W; Steven N; Leese A; Steigerwald-Mullen P; Kurilla MG; Frappier L; Rickinson A
    Immunity; 1997 Dec; 7(6):791-802. PubMed ID: 9430224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
    Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
    Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
    J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
    Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
    Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
    J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
    Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
    Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
    J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
    J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
    Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
    Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.
    Krüger S; Schroers R; Rooney CM; Gahn B; Chen SY
    J Immunother; 2003; 26(3):212-21. PubMed ID: 12806275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
    Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
    J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
    Yin Y; Manoury B; Fåhraeus R
    Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.